

30 January 2026

BSF Enterprise PLC
("BSF" or the "Company")

Publication of Annual Report and Accounts

BSF Enterprise PLC (LSE: BSFA), a leading innovator in tissue-engineered materials, is pleased to announce that its Annual Report and Consolidated Financial Statements for the year ended 30 September 2025 have been published.

The Annual Report is now available to view on the Company's website at:

<https://bsfenterprise.com/reports-documents-and-presentations#reports>

In accordance with Listing Rule requirements, copies of the Annual Report will be submitted to the National Storage Mechanism and will shortly be available for inspection.

Highlights from the period include:

- Significant commercial and technical progress across core subsidiaries: 3D Bio-Tissues Limited (3DBT), Lab-Grown Leather Limited (LGL), and Kerato Limited
- Launch of CytoBoost™ bioactive media additive and continued expansion of City-Mix™ for cost-effective cultivated meat production
- Major breakthrough with the world's first 2mm-thick scaffold-free leather; ongoing collaborations with luxury fashion brands and advancement toward commercial production of T-Rex derived leather product
- Key licensing agreement secured with the University of Montreal for liquid cornea technology, supporting in-situ corneal repair; veterinary clinical trials planned for 2026 and human trials in 2027
- Strategic fundraising initiatives, including shareholder approval for up to £15 million via warrants, to support commercialisation, spin-outs, Greater China expansion, and potential acquisitions
- Reduced net loss to £1,013,527 (2024: £1,672,291) reflecting careful cost control and increased grant income

Engage with the BSF Enterprise management team directly by asking questions, watching video summaries and seeing what other shareholders have to say. Navigate to our Interactive Investor website here:

For further enquiries, please visit www.bsfenterprise.com or contact:

BSF Enterprise PLC Geoff Baker - Chairman Che Connon - CEO & Director We encourage all investors to share questions on this announcement via our investor website.	https://bsfenterprise.com/link/P7b6or
--	---

Shard Capital (Broker) Damon Heath Isabella Pierre	0207 186 9000 0207 186 9927
AlbR Capital Limited (Broker) Colin Rowbury Jon Belliss	+44 (0)20 7469 0930
<i>ISIN of the Ordinary Shares is GB00BHNBDQ51. SEDOL Code is BHNBDQ5.</i>	

Subscribe to our news alert service: <https://bsfenterprise.com/s/bb9f43>

About BSF Enterprise PLC

BSF Enterprise PLC (BSF) develops and commercialises cutting-edge tissue-engineered solutions, including lab-grown leather, cultivated meat, and corneal repair technologies. By leveraging its proprietary scaffold-free platform, BSF aims to deliver sustainable alternatives to traditional materials and meet global demand for environmentally responsible innovations.